Literature DB >> 20726930

Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall.

Keira L Barr1, Thomas H Konia, Maxwell A Fung.   

Abstract

Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.
Copyright © 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726930     DOI: 10.1111/j.1600-0560.2010.01592.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  1 in total

1.  Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling.

Authors:  Alain Meyer; Ghada Alsaleh; Claude Heuschling; Jacques-Eric Gottenberg; Philippe Georgel; Benard Geny; Seiamak Bahram; Jean Sibilia
Journal:  RMD Open       Date:  2016-10-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.